دورية أكاديمية
أعرض في EDS

Bacteriocin-Like Inhibitory Substances from Probiotics as Therapeutic Agents for Candida Vulvovaginitis.

التفاصيل البيبلوغرافية
العنوان: Bacteriocin-Like Inhibitory Substances from Probiotics as Therapeutic Agents for Candida Vulvovaginitis.
المؤلفون: Hefzy EM; Department of Medical Microbiology and Immunology, Faculty of Medicine, Fayoum University, Fayoum 63514, Egypt., Khalil MAF; Department of Microbiology and Immunology, Faculty of Pharmacy, Fayoum University, Fayoum 63514, Egypt., Amin AAI; Department of Medical Microbiology and Immunology, Faculty of Medicine, Fayoum University, Fayoum 63514, Egypt., Ashour HM; Department of Integrative Biology, College of Arts and Sciences, University of South Florida, St. Petersburg, FL 33701, USA.; Department of Microbiology and Immunology, Faculty of Pharmacy, Cairo University, Cairo 11562, Egypt., Abdelaliem YF; Department of Agricultural Microbiology, Faculty of Agriculture, Fayoum University, Fayoum 63514, Egypt.
المصدر: Antibiotics (Basel, Switzerland) [Antibiotics (Basel)] 2021 Mar 17; Vol. 10 (3). Date of Electronic Publication: 2021 Mar 17.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI AG Country of Publication: Switzerland NLM ID: 101637404 Publication Model: Electronic Cited Medium: Print ISSN: 2079-6382 (Print) Linking ISSN: 20796382 NLM ISO Abbreviation: Antibiotics (Basel) Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI AG, 2012-
مستخلص: Probiotics can potentially prevent and treat diseases. We examined the inhibitory activity of bacteriocin-like inhibitory substances (BLISs) from potentially probiotic lactobacilli and streptococci on Candida albicans and non- Candida albicans clinical isolates from women with vulvovaginitis. Using agar well diffusion assays, BLISs inhibited both Candida albicans and non- Candida albicans isolates. The BLIS from L. pentosus isolates had the highest anti- Candida activity (33/45; 73.3%), followed by BLISs from isolates of L. paracasei subsp. paracasei (31/45; 68.9%), L. rhamnosus I (30/45; 66.7%) , L. delbrueckii subsp. lactis I (30/45; 66.7%), and S. uberis II (30/45; 66.7%). Upon characterization according to the retained activity under variable physical and chemical conditions, the BLISs showed stability against heat, pH, and surfactants, but were protease-sensitive, which suggests a proteinaceous nature of the active substances. Using crystal violet assays, the BLISs reduced the Candida biofilm biomass significantly as compared to a control group that lacked BLISs. In vivo testing of the antagonistic activity was performed using the Galleria mellonella ( G. mellonella ) larvae model. BLISs significantly improved survival in G. mellonella larvae treated with Candida isolates on the first, second, and seventh days, as compared to larvae inoculated with Candida only ( p < 0.01). The results show that BLISs can be used as biotherapeutic agents in vulvovaginal candidiasis.
References: Malays J Med Sci. 2011 Oct;18(4):13-25. (PMID: 22589669)
J Med Microbiol. 2013 Jan;62(Pt 1):10-24. (PMID: 23180477)
PLoS One. 2014 Aug 11;9(8):e104508. (PMID: 25111806)
Biofouling. 2018 Feb;34(2):212-225. (PMID: 29380647)
Sci Rep. 2016 Jan 14;6:19366. (PMID: 26763314)
Lett Appl Microbiol. 2001 Apr;32(4):243-7. (PMID: 11298934)
Caries Res. 2017;51(2):87-95. (PMID: 28118640)
Contraception. 2006 Jan;73(1):78-81. (PMID: 16371300)
Nature. 1970 Aug 15;227(5259):680-5. (PMID: 5432063)
J Microbiol Methods. 2008 Feb;72(2):157-65. (PMID: 18155789)
J Appl Microbiol. 2004;96(3):521-34. (PMID: 14962132)
Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2818-23. (PMID: 19196973)
Front Microbiol. 2019 Feb 21;10:311. (PMID: 30846978)
J Med Microbiol. 2005 Oct;54(Pt 10):981-985. (PMID: 16157554)
Clin Microbiol Rev. 2003 Oct;16(4):658-72. (PMID: 14557292)
J Bacteriol. 1991 Jan;173(2):697-703. (PMID: 1987160)
J Gen Appl Microbiol. 2010 Apr;56(2):151-61. (PMID: 20513963)
Biomed Res Int. 2016;2016:7461047. (PMID: 27699173)
Int J Med Microbiol. 2014 Jul;304(5-6):654-61. (PMID: 24875405)
Appl Environ Microbiol. 1991 Jan;57(1):114-21. (PMID: 1903624)
Virulence. 2015;6(1):29-39. (PMID: 25654408)
J Appl Bacteriol. 1996 Apr;80(4):453-7. (PMID: 8849648)
AMB Express. 2012 Sep 10;2(1):48. (PMID: 22963659)
PLoS One. 2012;7(3):e33705. (PMID: 22479431)
Oral Dis. 2012 Apr;18(3):260-4. (PMID: 22059932)
J Physiol Pharmacol. 2009 Dec;60 Suppl 6:19-26. (PMID: 20224147)
J Appl Microbiol. 2017 Jan;122(1):201-211. (PMID: 27727499)
Med Mycol. 2009 Mar;47(2):137-43. (PMID: 18651308)
J Appl Microbiol. 2015 May;118(5):1180-90. (PMID: 25688886)
J Bacteriol. 2007 Feb;189(4):1189-98. (PMID: 17098898)
Microbiology (Reading). 2007 May;153(Pt 5):1619-1630. (PMID: 17464077)
Appl Microbiol Biotechnol. 2016 Jul;100(14):6415-6426. (PMID: 27087525)
PLoS One. 2015 Jun 22;10(6):e0131220. (PMID: 26098675)
Nucleic Acids Res. 1997 Sep 1;25(17):3389-402. (PMID: 9254694)
J Appl Microbiol. 1999 Nov;87(5):726-34. (PMID: 10594714)
Appl Environ Microbiol. 2012 Apr;78(7):2190-9. (PMID: 22267663)
Clin Infect Dis. 2015 Aug 15;61(4):601-6. (PMID: 25935553)
Appl Environ Microbiol. 2008 Jul;74(14):4539-42. (PMID: 18502927)
Arch Oral Biol. 2017 Apr;76:1-6. (PMID: 28063305)
Contraception. 2010 Apr;81(4):331-5. (PMID: 20227551)
J Antimicrob Chemother. 2006 Aug;58(2):266-72. (PMID: 16790461)
Microbiology (Reading). 2005 Sep;151(Pt 9):3051-3058. (PMID: 16151215)
J Clin Microbiol. 1996 Oct;34(10):2497-9. (PMID: 8880507)
Appl Environ Microbiol. 2006 Feb;72(2):1148-56. (PMID: 16461661)
Appl Environ Microbiol. 2007 Dec;73(23):7763-6. (PMID: 17933926)
Med Mycol. 2012 Feb;50(2):214-8. (PMID: 21539503)
Nihon Rinsho. 2009 Jan;67(1):157-61. (PMID: 19177766)
J Biol Chem. 1951 Nov;193(1):265-75. (PMID: 14907713)
فهرسة مساهمة: Keywords: Galleria mellonella; bacteriocins; biofilm; vulvovaginitis
تواريخ الأحداث: Date Created: 20210403 Latest Revision: 20210413
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC8002407
DOI: 10.3390/antibiotics10030306
PMID: 33802636
قاعدة البيانات: MEDLINE
الوصف
تدمد:2079-6382
DOI:10.3390/antibiotics10030306